Assura (LON:AGR) Earns Neutral Rating from JPMorgan Chase & Co.

Assura (LON:AGR – Get Rating)‘s stock had its “neutral” rating restated by investment analysts at JPMorgan Chase & Co. in a research note issued on Wednesday, Marketbeat Ratings reports. They presently have a GBX 56 ($0.70) target price on the real estate investment trust’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 16.52% from the company’s previous close.

A number of other research analysts also recently commented on AGR. Peel Hunt reissued a “buy” rating and set a GBX 65 ($0.81) target price on shares of Assura in a research report on Tuesday. Shore Capital restated a “buy” rating on shares of Assura in a report on Tuesday. Finally, Barclays restated an “overweight” rating and issued a GBX 57 ($0.71) price target on shares of Assura in a report on Wednesday. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Assura has an average rating of “Moderate Buy” and an average price target of GBX 60.75 ($0.76).

Assura Trading Down 3.0 %

LON AGR opened at GBX 48.06 ($0.60) on Wednesday. The company has a debt-to-equity ratio of 70.19, a quick ratio of 2.84 and a current ratio of 2.89. The company has a market capitalization of £1.42 billion, a price-to-earnings ratio of 1,201.50, a price-to-earnings-growth ratio of 3.60 and a beta of 0.27. The company’s 50-day simple moving average is GBX 50.29 and its two-hundred day simple moving average is GBX 52.93. Assura has a one year low of GBX 46.88 ($0.58) and a one year high of GBX 72.35 ($0.90).

Assura Company Profile

(Get Rating)

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create outstanding spaces for health services in our communities.